Metastatic Site–Specific Outcomes With 1L ccRCC Therapies
Panelists discuss how metastatic site–specific outcomes with first-line therapies for clear cell renal cell carcinoma (ccRCC) provide insights into the efficacy of treatment strategies based on the location of metastases.
Video Player is loading.
EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma
Now Viewing
EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies
EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC
EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns
EP: 5.Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.
EP: 6.CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making
EP: 7.Future Directions in Advanced RCC
Recent Videos
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
The Role of ctDNA in CRC
CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
Related Content
